Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.

[1]  E. Cho,et al.  A Phase II Study of Erlotinib as a First-Line Therapy for Patients with Non—Small-Cell Lung Cancer with Favorable Clinical Predictors , 2008 .

[2]  Heung Tae Kim,et al.  Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first , 2008, Cancer.

[3]  M. Rinaldi,et al.  Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases , 2007, Cancer.

[4]  M. Maemondo,et al.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Brown,et al.  Whole-brain radiotherapy in the management of brain metastasis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Mehta,et al.  Current management of brain metastases, with a focus on systemic options. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Kris,et al.  High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib , 2005, Cancer.

[8]  Hyae-Young Kim,et al.  Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers , 2005, Clinical Cancer Research.

[9]  K. Kiura,et al.  Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.

[10]  P. Brown,et al.  Cognitive sequelae of brain radiation in adults. , 2004, Seminars in oncology.

[11]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Yawn,et al.  Temporal and gender-related trends in brain metastases from lung and breast cancer. , 2003, Minnesota medicine.

[13]  L. Deangelis,et al.  Radiation‐induced dementia in patients cured of brain metastases , 1989, Neurology.

[14]  C. Chiu,et al.  Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. , 2005, Lung cancer.

[15]  H. Minn,et al.  Prognosis of patients treated for intracranial metastases with whole-brain irradiation. , 1998, Annals of medicine.

[16]  Harvey I. Pass,et al.  Lung cancer : principles and practice , 1996 .

[17]  R A Patchell,et al.  Brain metastases. , 1991, Neurologic clinics.